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A B S T R A C T
Purpose
EURAMOS-1, an international randomized controlled trial, investigated maintenance therapy with
pegylated interferon alfa-2b (IFN--2b) in patients whose osteosarcoma showed good histologic
response (good response) to induction chemotherapy.
Patients and Methods
At diagnosis, patients age  40 years with resectable high-grade osteosarcoma were registered.
Eligibility after surgery for good response random assignment included  two cycles of preoperative
MAP (methotrexate, doxorubicin, and cisplatin), macroscopically complete surgery of primary tumor,
 10% viable tumor, and no disease progression. These patients were randomly assigned to four
additional cycles MAP with or without IFN--2b (0.5 to 1.0 g/kg per week subcutaneously, after
chemotherapy until 2 years postregistration). Outcome measures were event-free survival (EFS;
primary) and overall survival and toxicity (secondary).
Results
Good response was reported in 1,041 of 2,260 registered patients; 716 consented to random
assignment (MAP, n  359; MAP plus IFN--2b, n  357), with baseline characteristics balanced
by arm. A total of 271 of 357 started IFN--2b; 105 stopped early, and 38 continued to receive
treatment at data freeze. Refusal and toxicity were the main reasons for never starting IFN--2b
and for stopping prematurely, respectively. Median IFN--2b duration, if started, was 67 weeks. A
total of 133 of 268 patients who started IFN--2b and provided toxicity information reported grade
 3 toxicity during IFN--2b treatment. With median follow-up of 44 months, 3-year EFS for all 716
randomly assigned patients was 76% (95% CI, 72% to 79%); 174 EFS events were reported
(MAP, n 93; MAP plus IFN--2b, n 81). Hazard ratio was 0.83 (95% CI, 0.61 to 1.12; P .214)
from an adjusted Cox model.
Conclusion
At the preplanned analysis time, MAP plus IFN--2b was not statistically different fromMAP alone.
A considerable proportion of patients never started IFN--2b or stopped prematurely. Long-term
follow-up for events and survival continues.
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INTRODUCTION
Osteosarcoma is themost frequent primary sarcomaof bone, primar-
ily diagnosed in adolescents and young adults; however, it is rare
overall, with only two to three affected individuals per million
person-years. Most recent regimens have included several weeks of
preoperative chemotherapy, followed by surgery and several months
postoperative chemotherapy.1 Reported outcomes have been similar
internationally and have shown little improvement over previous
decades.2,3 Histologic response to preoperative chemotherapy is an
important prognostic factor. A good histologic response is usually
classified as  10% viable tumor in the resected specimen. Good
respondershavehadbetter5-year survival thanpoor responders (75%
to 80% v 45% to 55%).1,4
Four international osteosarcoma groups with a history of suc-
cessfully conducted clinical trials5-9 formed the European and Amer-
ican Osteosarcoma Study Group (EURAMOS)10,11: the Children’s
Oncology Group (COG), Cooperative Osteosarcoma Study Group
(COSS), European Osteosarcoma Intergroup (EOI), and Scandina-
vian SarcomaGroup (SSG). The EURAMOS-1 trial established large-
scale multinational cooperation in clinical trials for osteosarcoma.11
MAP (methotrexate, doxorubicin, and cisplatin) chemotherapy was
accepted as standard.8,12 Intensified salvage chemotherapy was inves-
tigated in poor responders. On the basis of preclinical and clinical
evidence,13 we decided to investigate the value of maintenance treat-
ment with interferon alfa (IFN-) in good responders.
Maintenance treatment iswell established inacute lymphoblastic
leukemia14 and is being investigated in sarcomas.15 IFN- has anti-
proliferative, differentiation-inducing, apoptotic, and antiangiogenic
properties, and its clinical activity has been demonstrated in several
cancers, including as postchemotherapy maintenance.13,16-19 It has
been associated with activity against osteosarcomas (some of which
have expressed IFN-/ receptor20) in vitro, in animalmodels, and in
patients with metastatic disease.13 Most notably, single-institution
treatment of 89 consecutive patients with semipurified leukocyte
IFN- as the only adjuvant treatment after surgery resulted in 10-year
metastasis-free and sarcoma-specific survival rates of 39% and 43%,
respectively.21On the basis of this rationale, we aimed to test IFN- as
maintenance treatment in osteosarcoma.13 The objective of our ran-
dom assignment was to examine whether addition of a pegylated
formulation of interferon alfa-2b (IFN--2b) asmaintenance therapy
after postoperative MAP would improve outcomes, with event-free
survival (EFS) as the primary outcomemeasure.
PATIENTS AND METHODS
Setting
EURAMOS-1 was an open-label phase III randomized controlled trial
(RCT) for patients with localized ormetastatic high-grade osteosarcoma con-
sidered suitable for complete surgical resection. Eligibility for registration has
been described previously.10,11 Key criteria were localized or metastatic high-
grade osteosarcoma of an extremity or the axial skeleton (with exception of
craniofacial sites), with all disease sites potentially amenable to complete sur-
gical resection, and age 40 years.
All patients received induction MAP followed by surgery of the
primary. Thereafter, patients age 5 years who had completed two cycles
of induction MAP, had undergone macroscopically complete resection of
their primary tumor, had  10% viable tumor on histologic response
assessment, andhadno evidence of disease progressionwere eligible for the
good response random assignment. Histologic response assessment was
conducted locally before random assignment and later confirmed by a trial
reference pathologist. Random assignment had to be performed 35 days
after surgery. Patients age 5 years at potential random assignment were
excluded from random assignment because of reports of neurologic com-
plications in young children receiving IFN- for other diseases.22 Partici-
pants and/or their legal guardians, as appropriate, provided written
informed consent to registration and random assignment. Regulatory and
ethics approvals were obtained according to national requirements.
Trial Treatments and Procedures
Induction MAP (weeks 1 to 10) comprised two 5-week cycles of doxo-
rubicin 75mg/m2 of body-surface area, cisplatin 120mg/m2, andmethotrex-
ate 12 g/m2, followed by surgery of the primary in week 11. Doxorubicin and
cisplatinwere administered inweeks 1 and6andmethotrexate inweeks 4 ,5, 9,
and 10 (Fig 1, treatment scheme; Data Supplement). Up to two additional
doses of methotrexate were permitted preoperatively if surgery had to be
delayed. The protocol (Data Supplement) contained detailed guidance on
mandatory tests and requirements for each treatment cycle, supportive care,
and dose adjustments. If present, primary metastases were to be surgically
removed in weeks 11 to 20.
After histologic assessment of the resected tumor, consenting patients
were randomly assigned in a one-to-one ratio to four postoperative cycles of
MAP (weeks 12 to 29; cisplatin omitted in last two cycles) or to the same
regimen followed by maintenance pegylated IFN--2b (Fig 1). Treatment
allocation was performed using concealed permuted blocks with three strati-
fication factors: trial group (COG, COSS, EOI, or SSG), location of tumor
(proximal femur or proximal humerus v other limb v axial skeleton), and
presence of metastases (no v yes or possible). Lung metastases, detected by
spiral computed tomography scanning, were considered certain if there were
threeormore lesions5mminmaximumdiameteror a single lesion1cm.
Scans of patients registering metastatic disease with fewer or smaller lesions
were classified as possiblemetastatic disease. Patients were randomly assigned
centrally through the Medical Research Council Clinical Trials Unit (COSS,
EOI, and SSG) or COG.
Subcutaneous IFN--2b was plannedweekly fromweek 30 to 104 at 0.5
g/kg perweek (maximum, 50g) for 4weeks and increased to 1.0g/kg per
week (maximum, 100 g) thereafter if no flu-like symptoms worse than
CommonToxicity Criteria for Adverse Events (version 3.0)23 grade 2 or other
toxicities worse than grade 1 were experienced.
Assessments
During MAP treatment, clinical and toxicity assessments were per-
formed before each drug administration. During IFN--2b, patients were
monitored twice perweek for 8weeks andonce or twice permonth thereafter.
Adverse events were graded according to the Common Toxicity Criteria for
Adverse Events (version 3.0)23 and reported centrally as the maximum grade
during pre- and postoperative chemotherapy and maximum grade per
3-month period during IFN--2b. Toxicity was assessed in each patient until
trial treatment was stopped. Late toxicity throughout follow-up was collected
at COSS, EOI, and SSG.
All patients were assessed for local and distant recurrence at predefined
intervals by physical examination and radiography of the chest and primary
site. Radiographically detected relapse was also imaged by computed tomog-
raphy, magnetic resonance imaging, and/or bone scans and, if appropriate,
confirmed by histology. Patients were observed regularly for  5 years after
treatment (Data Supplement).
Statistical Analyses
The primary outcome measure was EFS, defined as time from random
assignment until a first event (local recurrence, new metastatic disease, pro-
gression of primary metastatic disease, secondary malignancy, or death) or
censoring at last contact. Secondary outcomemeasures included: overall sur-
vival (OS; time from randomassignment until death resulting from any cause
or last contact), short- and long-term toxicities, and quality of life, which will
be the topic of separate analyses.
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To detect absolute improvements of 10% from 70% to 80% in 3-year
EFS (hazard ratio [HR], 0.63 in favor of IFN--2b) with two-sided 5% signif-
icance level and 80%power required 147EFS events.24 The same applied to
an improvement in5-yearOS from70%to80%, requiring147deaths in the
longer term. The initial plan to register 1,400 patients (to randomly assign 1,260
[good responders, n 567; poor responders, n 693]) was revised to approxi-
mately 2,000 patients because of a lower randomization rate and relatively fewer
poor responders than anticipated.11 Interim data were reviewed annually by an
independent data monitoring committee and could have been reported early if
eitherP .001 for EFS25,26 or severe IFN safety issueswere identified.
A prespecified subgroup of patients with localized disease comprised
those without definitive metastases at registration. To detect a 10% improve-
ment from75%to85%in3-yearEFSand5-yearOS(HR,0.56)with two-sided
5% significance and 80% power required 98 events.
The primary analysis used intention-to-treat principles. The Kaplan-
Meier method was used to estimate survival functions, log-rank tests for
differences between survival curves, and Cox models (adjusted for stratifica-
tion factors) to estimate treatment effects, with suitability checked by tests for
proportionality of hazards.All comparisonswere expressed relative to control,
with HR  1 favoring IFN--2b. Consistency of treatment effect was
examined using the interaction test (2 test for heterogeneity) in subgroups
defined posthoc: sex, age, site of disease, location on bone, lung metastases,
nonlungmetastases, and histologic subtype.Median follow-upwas calculated
using reverse censoring on death.
In a prespecified exploratory analysis, EFSwas computed from23weeks
after starting postoperative chemotherapy, excluding patients who experi-
enced progression before the expected start of IFN--2b. IFN--2b dose was
summarized only for patients who could have completed and reported com-
pleting IFN--2b by the data freeze (patients registered before November 15,
2010). Analyses were performed using Stata software (versions 12.1 and 13.1;
Stata, College Station, TX).
RESULTS
Patients
Between April 2005 and June 2011, 2,260 patients were
registered from  300 sites in 17 European, North American,
and Australasian countries. The data were frozen on February
15, 2013, because the event target was reached. A total of 1,041
patients were good responders, and 716 (69%) from 246 trial
sites were randomly assigned (MAP, n  359; MAP plus IFN-
-2b, n  357; Fig 2). COG, COSS, EOI, and SSG randomly
assigned 300, 206, 161, and 49 patients, respectively. Table 1 lists
registration characteristics for these randomly assigned pa-
tients. Median age was 14 years (interquartile range [IQR], 11 to
16), and 421 (59%) were male; 630 (88%) had localized disease,
and 86 (12%) had primary metastases; of these, 66 had lung-
only, 15 had extrapulmonary-only, and five had both lung and
extrapulmonary metastases.
Median follow-up was 44 months (IQR, 28 to 58) for MAP
and 44 months (IQR, 29 to 58) for MAP plus IFN--2b. Twenty
patients (6%) in each arm were permanently lost to follow-up.
For patients last reported as alive, 94% were seen  14 months
before data freeze.
Treatment
Postoperative MAP. Postoperative MAP was delivered simi-
larly in both treatment arms. Median standardized postoperative
dose of methotrexate was 95 g/m2 (target, 96g/m2); doxorubicin,
298 mg/m2 (target, 300 mg/m2); and cisplatin, 239 mg/m2 (target,
240 mg/2; Data Supplement).
IFN--2b
Of 357 patients randomly assigned to MAP plus IFN--2b, 82
(23%) reported not starting; information was missing for four (1%).
Themostcommonreasonfornot startingwas treatment refusal (78%;
Fig 2). Of the 357 patients, 271 (76%) started IFN--2b at median 23
weeks after randomassignment.Atdata freeze, 128 (47%)of these271
patients reported completing protocol treatment, 105 (39%) of 271
reported stopping early, and 38 (14%) of 271 reported still receiving
Fig 1. Treatment scheme. IFN--2b, interferon alfa-2b;MA,methotrexate, doxorubicin;MAP,methotrexate, doxorubicin, and cisplatin; R, randomassignment; SC, subcutaneously.
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treatment. Reported reasons for early terminationwere: toxicity (n
47; 45%), osteosarcoma progression (n 25; 24%), refusal or patient
choice (n 18; 17%), clinician decision (n 7; 7%), problems with
wound healing or periprosthetic infections (n  6; 6%), and other
reasons (pregnancy, n 1; lost, n 1; Fig 2). Of the 271 patients, 132
(49%)required IFN--2bdose reductionsordelays.The target cumu-
lative IFN--2b dose was 72 g/kg. In 319 patients who could have
completed IFN--2bby thedata freeze, theobservedmediandosewas
25.8 g/kg (IQR, 0.5 to 60.0). Of these 319 patients, 240 reported
starting IFN--2b; among these 240, median dose was 40.0 g/kg
(IQR, 14.5 to 65.0; Data Supplement). Median duration of therapy
was 67 weeks (IQR, 25 to 75).
Registration
(N = 2,260) Not good responders
   Poor responders
   Response not reported
(n = 1,219)
(n = 1,059)
(n = 160)
Started MAP
   Withdrew before starting MAP
   Received at least 8 cycles of methotrexate, 4 cycles
      of doxorubicin, and 2 cycles of cisplatin
MAP treatment
(n = 358)
(n = 1)
(n = 260)
Started MAP
   No data reported
   Received at least 8 cycles of methotrexate, 4 cycles 
      of doxorubicin, and 2 cycles of cisplatin
MAP treatment
(n = 356)
(n = 1)
(n = 264)
Did not start IFN-α-2b
     
     Did not receive IFN-α-2b
         Treatment refusal
         Disease progression or recurrence
         Major deviation from protocol therapy
         Chemotherapy toxicity
         Clinician’s choice
         Thyroid dysfunction
         Poor responder wrongly randomly
             allocated as good (treated with MAP)
     No data yet available
(n = 86; 24%)
(n = 82)
(n = 64; 78%)
(n = 8; 10%)
(n = 4; 5%)
(n = 2; 2%)
(n = 2; 2%)
(n = 1; 1%)
(n = 1; 1%)
(n = 4)
Started IFN-α-2b
     
     Reported completing
     Still on treatment at data freeze
     Stopped early
         Disease progression
         Interferon toxicity
         Refusal/patient choice
         Clinician’s choice
         Problems with wound healing or
              periprosthetic infections
         Pregnancy
         Lost to follow-up
(n = 271; 76%)
(n = 128; 47%)
(n = 38; 14%)
(n = 105; 39%)
(n = 25; 24%)
(n = 47; 45%)
(n = 18; 17%)
(n = 7; 7%)
(n = 6; 6%)
(n = 1; 1%)
(n = 1; 1%)
Not allocated (n = 325)
Confirmed good responder
(n = 1,041)
Randomly allocated
(n = 716)
Included in analyses
EFS events
      Metastatic disease
      Local recurrence
      Secondary malignancy
      Metastatic disease and local recurrence
      Combination of events unknown
      Death
      Unrecorded type of event
Deaths
Main analysis
(n = 359)
(n = 93)
(n = 78; 85%)
(n = 10; 11%)
(n = 1; 1%)
(n = 1; 1%)
(n = 1; 1%)
(n = 1; 1%)
(n = 1; 1%)
(n = 46)
Included in analyses
EFS events
      Metastatic disease
      Local recurrence
      Metastatic disease and local recurrence
      Metastatic disease and secondary malignancy
      Combination of events is unknown
      Unrecorded type of event
Deaths
Patient last seen at random allocation
Main analysis
(n = 357)
(n = 81)
(n = 65; 81%)
(n = 7; 9%)
(n = 4; 5%)
(n = 1; 1%)
(n = 2; 3%)
(n = 2; 3%)
(n = 38)
(n = 1)
Last contact in last 14 months
Last contact > 14 months ago
Permanently lost to follow-up
Died
Follow-up
(n = 285)
(n = 14)
(n = 20)
(n = 38)
Last contact in last 14 months
Last contact > 14 months ago
Permanently lost to follow-up
Died
Follow-up
(n = 271)
(n = 22)
(n = 20)
(n = 46)
MAP
(n = 359)
MAP + IFN-α-2b
(n = 357)
Fig 2. CONSORT diagram. EFS, event-free survival; IFN--2b, interferon alfa-2b; MAP, methotrexate, doxorubicin, and cisplatin.
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Efficacy
EFS at 3 years for all 716 randomly assigned patients was 76%
(95%CI, 72%to79%).A total of 174 eventswere reported (MAP,n
93; MAP plus IFN--2b, n 81; Fig 2). In both arms, patients’ first
events mostly included metastases (MAP, n 79; MAP plus IFN--
2b, n 70). Local recurrencewas involved in 22 of the 174first events
(MAP, n  11; MAP plus IFN--2b, n  11). Of these, 17 were
isolated local recurrences, andfivewere combinedwithdistantmetas-
tases. One secondary malignancy (acute myeloid leukemia) was re-
ported as a first event (MAP-alone arm). Type of first event was not
reported for three patients (MAP, n 1;MAPplus IFN--2b, n 2).
Treatment effect for IFN--2bwas estimated asHRof 0.83 (95%
CI, 0.61 to1.12;P .214).Rates of 3-yearEFS forMAPandMAPplus
IFN--2bwere74%(95%CI, 69%to79%)and77%(95%CI, 72%to
81%), respectively (Fig 3A).
In 630 patients with localized disease, 135 EFS events were re-
ported (MAP, n 72; MAP plus IFN--2b, n 63). The estimated
treatment effect was consistent with the whole trial population (HR,
0.83; 95%CI, 0.59 to 1.17; P .284); 3-year EFS estimates were 77%
(95%CI, 71% to 82%) and 80% (95%CI, 75% to 84%) forMAP and
MAP plus IFN--2b, respectively.
A total of 84 deaths were reported (MAP, n  46; MAP plus
IFN--2b,n38;Fig3B).This early estimateof survivalhadanHRof
0.77 (95%CI, 0.50 to1.19); 5-yearOSwas81%(95%CI, 74%to86%)
for MAP and 84% (95% CI, 78% to 88%) for MAP plus IFN--2b.
Follow-up continues for survival.
Toxicity
The toxicity of preoperative chemotherapy has previously been
reported.11 During postoperative MAP, toxicity was mostly hemato-
logicanddidnotdifferbyarm(DataSupplement).Onepatientdiedas
a result of toxicity (cardiomyopathy); worst toxicity was grade 4 for
628 (88%) and grade 3 for 59 (8%) of 716 patients.
With regard to IFN--2b, toxicity data were reported for 268 of
271 patients who started IFN--2b. No fatal toxicities were reported
(Table 2). The worst toxicity during IFN--2b was grade 4 for 32
(12%) of 268 patients (primarily hematologic [n 26] or left ventric-
ular systolicdysfunction[LVSD;n4]); grade3wasworst toxicity for
101 (38%) and grade 1 to 2 for 105 (39%) of 268 patients. Three
suspected unexpected serious adverse reactions related to IFN--2b
were reported: two new cases of LVSD and one knee joint effusion.
From routinely collected long-term toxicity data, seven (4%) of
193 patients receiving MAP and eight (4%) of 199 patients receiving
MAP plus IFN--2b reported grade 3 to 4 LVSD (Data Supplement).
One additional grade 4 LVSDwas reported as a serious adverse event
during follow-up.
Exploratory Analyses
Exploratory subgroup analyses found no evidence of heteroge-
neity in treatment effect (Fig 3C; Data Supplement). An exploratory
EFS analysis (Fig 3D) separated patients allocated to MAP plus IFN-
-2b who started IFN--2b from those who did not start and com-
pared themwith patients allocated toMAP. Patientswhodid not start
their allocated IFN--2b seemed to do worse than patients not allo-
cated to IFN--2b.The exploratory analysis ofEFScomputed from23
weeks after start of postoperative chemotherapy included 702patients
who had not previously experienced progression. HR was 0.83 (95%
CI, 0.61 to 1.12), similar to the overall EFS estimate.
DISCUSSION
We investigatedmaintenance pegylated IFN--2b for patients whose
resectable osteosarcomas showed good histologic response to MAP
Table 1. Patient Characteristics at Registration
Characteristic
MAP
(n  359)
MAP Plus
IFN--2b
(n  357)
Total
(N  716)
No. % No. % No. %
Sex
Male 211 59 210 59 421 59
Female 148 41 147 41 295 41
Age at registration, years
 5 0 0 1 0 1 0
5-9 58 16 44 12 102 14
10-19 275 77 288 81 563 79
20-29 22 6 17 5 39 5
 30 4 1 7 2 11 2
Median 14 14 14
IQR 11-16 12-16 11-16
Site of tumor
Femur 179 50 191 54 370 52
Tibia 113 31 102 29 215 30
Fibula 14 4 20 6 34 5
Humerus 36 10 33 9 69 10
Radius 5 1 5 1 10 1
Ulna 2 1 0 0 2 0
Scapula/clavicle 2 1 1 0 3 0
Pelvis/sacrum 5 1 5 1 10 1
Rib 3 1 0 0 3 0
Location of tumor
Proximal 156 43 150 42 306 43
Diaphysis 13 4 12 3 25 3
Distal 180 50 189 53 369 52
NA (not long bone) 10 3 6 2 16 2
Pathologic fracture at diagnosis
No 321 90 308 86 629 88
Yes 37 10 49 14 86 12
Missing 1 NA 0 NA 1 NA
Lung metastases
No 295 82 288 81 583 81
Possible 29 8 33 9 62 9
Yes 35 10 36 10 71 10
Other metastases
No 343 96 348 97 691 97
Possible 3 1 2 1 5 1
Yes 13 4 7 2 20 3
WHO 2002 classification of
osteosarcoma27
Conventional 320 90 322 92 642 91
Telangiectatic 25 7 20 6 45 6
Small cell 2 1 1 0 3 0
High-grade surface 3 1 5 1 8 1
Other 4 1 2 1 6 1
Missing 5 NA 7 NA 12 NA
Abbreviations: IFN-2b, interferon alfa-2b; IQR, interquartile range; MAP,
methotrexate, doxorubicin, and cisplatin; NA, not applicable;
Possible metastases were collected only by Cooperative Osteosarcoma
Study Group, European Osteosarcoma Intergroup, and Scandinavian
Sarcoma Group.
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induction chemotherapy. The point estimate of treatment effect
showed improved EFS and OS. However, neither was statistically
significant, and the CIs were consistent with no effect. No change in
practice is indicated by these data.
We were able to ask this question, as well as a parallel question
concerning chemotherapy intensification in patients whose osteosar-
comas had poor histologic response, only because of the cooperative
efforts of four multi-institutional groups.10,11 This will provide a
framework for future trials.
With an age range up to 40 years and inclusion of patients with
resectable axial and/or primary metastatic disease, our study had
broader eligibility than many others. However, all patients had their
primary tumors resected, and all of these had shown a good response
to chemotherapy. The observed 3-year EFS of 76% for the 716 ran-
domly assigned patients meeting our eligibility criteria is in the range
of those previously observed for good responders.4,9,12,28 Approxi-
mately four fifths of first events were exclusivelymetastatic, and there
was no suggestion of an altered distribution of type of event by treat-
ment arm.
Toxicity observed during preoperative MAP was as expected7
and did not differ by allocation. Death related to toxicity during
postoperative MAP was limited to one case of cardiomyopathy.
Nevertheless, most patients reported grade 4 toxicities, mostly hema-
tologic, attesting to the treatment burden of osteosarcoma chemo-
therapy. As expected,13,29 toxicities observed during IFN--2b were
mainly grade 1 to 2. However, grade 3 and 4 toxicities were reported
for one half of patients who started IFN--2b, mostly hematologic.
Several patients developed signs of cardiac failure during IFN--2b.
Although we cannot exclude a contribution from IFN--2b to this
complication, we note these patients had previously received doxoru-
bicin 450 mg/m2 and that a similar number of control-arm patients
also developed LVSD. Given the high cumulative anthracycline dose,
the overall incidence of severe clinical cardiac toxicity in this
mainly adolescent population receiving a high cumulative anthra-
cycline dose by continuous infusion, rather than as a bolus, does
not seem excessive.30
The point estimates of the HR favored IFN--2b maintenance
for both EFS and OS, but the CIs were consistent with no effect. The
Fig 3. (A) Event-free survival; (B) overall survival; (C) exploratory subgroup analysis; (D) exploratory comparison. Nos. in parentheses in risk tables of parts A, B, and
D indicate No. of patients who had an event during the specified time period. HR, hazard ratio. IFN--2b, interferon alfa-2b; MAP, methotrexate, doxorubicin, and
cisplatin.
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observed effect size for EFS (HR, 0.83; 95% CI, 0.61 to 1.12) was
similar to that reported for another biologic agent, liposomal mu-
ramyl tripeptide phosphatidylethanolamine (HR, 0.80; 95% CI, 0.62
to 1.0),8 but smaller than our 0.63 target.
The interpretation of our findings is limited, because approxi-
mately one quarter of patients allocated to IFN--2b never started it.
Furthermore, not all patients continued IFN--2b after having start-
ed; only 128 of 357 patients reported completing the planned
protocol treatment. These issues of initiation and adherence arose
even though neither the dose nor schedule of IFN--2b nor the
duration of treatment was unusual,16,18,19,31 and a pegylated prep-
aration was expected to result in fewer adverse effects.13,16
Onemay speculate why the attrition rate for IFN--2bwas high.
Patient choicewas themost common reason for non–randomassign-
ment and for never starting IFN--2b among allocated patients and a
common reason for its premature termination.We assume that both
previous exposure to 29 protocol weeks of chemotherapy and
awareness of a favorable prognosis for good responders affected
compliance. A recent RCT of IFN- maintenance for relapsed
lymphoma faced similar abandonment problems. Those research-
ers concluded that it was not clear whether the absence of a demon-
strable advantage reflected a lack of intrinsic activity or indicated
the inability to administer an adequate dose of IFN to patients for
sustained periods.32
At first glance, our observations might call for an as-treated
analysis comparing those who initiated IFN--2b against the control
arm. However, patients allocated to IFN--2b who never started the
drug fared worse than patients never allocated to receive IFN--2b in
the first place, for reasons that are currently obscure.
Would a treatment effect have becomemore obvious if the cho-
sen IFN--2b dose had been higher or the treatment period longer?
Even in melanoma, where many RCTs of IFN have been per-
formed, evidence supporting a specific IFN dose, duration, or
formulation and identification of subsets of patients beyond those
with detectable residual disease most likely to benefit remain de-
batable issues, with no RCT showing additional benefit for treat-
ment extending beyond 12 to 18 months.19,33 For osteosarcoma,
such evidence is completely absent. The timing of IFN--2b ther-
apy is similarly uncertain. Although IFN- may enhance the sen-
sitivity of osteosarcomas to selected chemotherapeutic agents,34
there are no data demonstrating that IFN--2b can be safely ad-
ministered concurrently with MAP and no data indicating that it
would be more efficacious.
Was thegood responder cohort,with its relatively lowrecurrence
risk, ideal to observe effects of IFN--2b? Good responders generally
have a lower burden of micrometastatic residual disease (because
of chemosensitivity of their osteosarcomas) than poor responders,
and IFN may work best in such a context of minimal residual
disease. This is exemplified by adjuvant data from melanoma,
where IFN activity was confined to a subpopulation with micro-
scopic nodal disease.19,35
In conclusion, our collaborative group completed a large
prospective RCT in a rare condition within a reasonable timespan.
Although the point estimates for EFS and OS favored the
intervention—maintenance with pegylated IFN--2b—the CIs of
the HRs included 1, and we conclude no difference; the observed
effect size for EFS was smaller than targeted. A considerable pro-
portion of patients allocated to IFN--2b never started or did not
complete treatment with the drug, which complicates interpreta-
tion of the efficacy data. Reported toxicity in patients who started
IFN--2b did not seem excessive.
Although we have reached the target number of EFS events,
ongoing follow-up of patients is crucial and will permit the planned
analysis of OS. The current EFS results, reported at the protocol-
defined analytic end point, do not support the routine use of IFN-
-2bmaintenance after standard chemotherapy for osteosarcoma.
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Table 2.Worst-Grade Toxicities Reported During IFN-2b Treatment
Toxicity
Worst Grade
0 1-2 3 4
No. % No. % No. % No. %
Any 30 11 105 39 101 38 32 12
Routinely collected
toxicities†
Neutrophils 72 38 39 21 65 34 14 7
Leucocytes 76 29 158 59 25 9 7 3
Platelets 142 53 112 42 6 2 6 2
Mood alteration
(depression) 193 75 55 21 8 3 1 0
Fever 156 59 107 40 1 0 1 0
Hemoglobin 131 49 127 48 8 3 0 0
Fatigue 134 50 129 49 3 1 0 0
Cardiac arrhythmia 243 96 7 3 3 1 0 0
Rigor/chills 202 75 64 24 2 1 0 0
Vomiting 236 89 28 11 2 1 0 0
Diarrhea 239 90 25 9 2 1 0 0
Bilirubin 245 92 18 7 2 1 0 0
Weight loss 231 87 35 13 1 0 0 0
Thyroid dysfunction 242 92 20 8 1 0 0 0
Creatinine 250 94 15 6 1 0 0 0
Mucositis 174 94 12 6 0 0 0 0
Other notable serious AEs
and toxicities‡
LVSD NA NA 1 0 2 1 4 2
Amylase NA NA 0 0 0 0 1 0
Mood alteration
(agitation) NA NA 0 0 0 0 1 0
Infection (normal
neutrophils)§ NA NA 2 1 6 2 0 0
Flu-like syndrome NA NA 12 5 0 0 0 0
Pain (muscle) NA NA 4 2 4 2 0 0
Pain (head/headache) NA NA 12 5 0 0 0 0
Pain (extremity/limb) NA NA 5 2 0 0 0 0
NOTE. Includes all routinely collected toxicities and any other toxicities with
reported incidence in  five patients of any grade or of grade  4 in one
patient.
Abbreviations: AE, adverse event; CRF, case report form; IFN-2b, interferon
alfa-2b; LVSD, left ventricular systolic dysfunction; NA, not applicable.
Based on No. of patients reporting each type of toxicity.
†Routinely collected on CRF.
‡Spontaneously reported on CRF or as serious AE.
§Or grade 1 to 2 neutrophils.
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GLOSSARY TERMS
cisplatin: an inorganic platinum agent (cis-diamminedichloro-
platinum) with antineoplastic activity. Cisplatin forms highly
reactive, charged, platinum complexes, which bind to nucleo-
philic groups such as GC-rich sites in DNA, inducing intrastrand
and interstrand DNA cross-links as well as DNA-protein
cross-links. These cross-links result in apoptosis and cell
growth inhibition. Carboplatin and oxaliplatin are other
members of this class.
Cox proportional hazards regressionmodel: a statis-
tical model for regression analysis of censored survival data,
examining the relationship of censored survival distribution to one or
more covariates. This model produces a baseline survival curve, covari-
ate coefficient estimates with their standard errors, risk ratios, 95% CIs,
and significance levels.
IFN--2b (interferon-alfa-2b): recombinant interferon alfa that
is commercially prepared from a bacterial fermentation of E. coli bearing
an expression vector containing the interferon alfa-2b (IFN--2b) gene
from human leukocytes.
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Wilmington, DE (Dr Christopher Frantz); All Children’s Hospital, St. Petersburg, FL (Dr Gregory Hale); Ann and Robert H Lurie
Children’s Hospital of Chicago, Chicago, IL (Dr David Walterhouse); Baptist Hospital of Miami, Miami, FL (Dr Doured Daghistani);
Baylor College of Medicine, Houston, TX (Dr Lisa Bomgaars); BI-LO Charities Children’s Cancer Center, Greenville, SC (Dr Nichole
Bryant); BronsonMethodistHospital,Kalamazoo,MI (Dr JeffreyLobel); BrookeArmyMedicalCenter, Fort SamHouston,TX(DrDella
Howell); BrooklynHospital Center, NewYork,NY (Dr Swayamprabha Sadanandan); BrowardHealthMedical Center, Fort Lauderdale,
FL (DrHectorRodriguez-Cortes);CSMottChildren’sHospital,AnnArbor,MI (DrRajenMody);CardinalGlennonChildren’sMedical
Center, St Louis, MO (Dr William Ferguson); Cardon Children’s Medical Center, Mesa, AZ (Dr Xiaxin Li); Carilion Clinic Children’s
Hospital, Roanoke, VA (Dr Mandy Atkinson); Carolinas Medical Center/Levine Cancer Institute, Charlotte, NC (Dr Joel Kaplan);
Cedars-SinaiMedical Center, LosAngeles, CA (Dr Fataneh (Fae)Majlessipour); Children’sHealthcare of Atlanta - Egleston, Atlanta, GA
(Dr Howard Katzenstein); Children’s Hospital and Medical Center of Omaha, Omaha, NE (Dr Minnie Abromowitch); Children’s
Hospital and Research Center at Oakland, Oakland, CA (Dr Carla Golden); Children’s Hospital Central California, Madera, CA (Dr
Vonda Crouse); Children’s Hospital Colorado, Aurora, CO (Dr Kelly Maloney); Children’s Hospital Medical Center of Akron, Akron,
OH (Dr Steven Kuerbitz); Children’s Hospital of Alabama, Birmingham, AL (Dr Alyssa Reddy); Children’s Hospital of Los Angeles, Los
Angeles, CA (Dr Leo Mascarenhas); Children’s Hospital of Philadelphia, Philadelphia, PA (Dr Frank Balis); Children’s Hospital of
PittsburghofUPMC,Pittsburgh,PA(DrArthurRitchey);Children’sHospital-MainCampus,NewOrleans, LA(DrLolieYu);Children’s
Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis, MN (Dr Bruce Bostrom); Children’s Mercy Hospitals and Clinics,
Kansas City, MO (Dr Maxine Hetherington); Children’s National Medical Center, Washington, DC (Dr Jeffrey Dome); Childrens
Hospital ofOrangeCounty,Orange,CA(DrViolet Shen);ChildrensHospital-King’sDaughters,Norfolk,VA(DrEric Lowe);Cincinnati
Children’s Hospital Medical Center, Cincinatti, OH (Dr John Perentesis); City of Hope, Duarte, CA (Dr Anna Pawlowska); Cleveland
Clinic Foundation, Cleveland, OH (Dr Margaret Thompson); Columbia University Medical Center, New York, NY (Dr Alice Lee);
Connecticut Children’sMedical Center, Hartford, CT (DrMichael Isakoff); CookChildren’sMedical Center, FortWorth, TX (DrMary
MeaghanGranger);Midwest Children’s Cancer Center,Milwaukee,WI (DrMichael Kelly);Miller Children’s Hospital, Long Beach, CA
(Dr Amanda Termuhlen);MissionHospitals Inc, Asheville, NC (DrOrren Beaty);MontefioreMedical Center -Moses Campus, Bronx,
NY (Dr Rosanna Ricafort);MorristownMedical Center,Morristown, NJ (Dr StevenHalpern);Mount SinaiMedical Center, NewYork,
NY (Dr Birte Wistinghausen); Natalie W Bryant Cancer Center, Tulsa, OK (Dr Gregory Kirkpatrick); Nationwide Children’s Hospital,
Colombus,OH(DrMarkRanalli);NavalMedicalCenter -Portsmouth, Fort SamHouston,TX(DrDellaHowell);NavalMedicalCenter
-San Diego, Fort Sam Houston, TX (Dr Della Howell); Nemours Children’s Clinic - Jacksonville, Jacksonville, FL (Dr Eric Sandler);
Nemours Children’s Clinic - Pensacola, Pensacola, FL (Dr Jeffrey Schwartz); Nemours Childrens Clinic - Orlando, Orlando, FL (Dr
Ramamoorthy Nagasubramanian); Nevada Cancer Research Foundation CCOP, Las Vegas, NV (Dr Jonathan Bernstein); New York
Medical College, Valhalla, NY (DrMehmet Ozkaynak); Newark Beth Israel Medical Center, Newark, NJ (Dr Peri Kamalakar); Ochsner
Clinic Foundation, NewOrleans, LA (Dr Rajasekharan (Raj)Warrier); Oregon Health and Science University, Portland, OR (Dr Linda
Stork); Palmetto Health Richland, Columbia, SC (Dr Ronnie Neuberg); Penn State Hershey Children’s Hospital, Hershey, PA (Dr Lisa
McGregor); Phoenix Childrens Hospital, Phoenix, AZ (Dr Jessica Boklan); Novant Health PresbyterianMedical Center, Charlotte, NC
(Dr Paulette Bryant); Primary Children’s Medical Center, Salt Lake City, UT (Dr Phillip Barnette); Providence Sacred Heart Medical
Center andChildren’sHospital, Spokane,WA(Dr Judy Felgenhauer); RadyChildren’sHospital - SanDiego, SanDiego,CA (DrWilliam
Roberts); Rainbow Babies and Childrens Hospital, Cleveland, OH (Dr Yousif (Joe) Matloub); Randall Children’s Hospital at Legacy
Emanuel, Portland, OR (Dr Janice Olson); Raymond Blank Children’s Hospital, Des Moines, IA (DrWendyWoods-Swafford); Rhode
IslandHospital, Providence, RI (DrKevin Schwartz); RileyHospital for Children, Indianapolis, IN (Dr Robert Fallon); RockyMountain
Hospital forChildren-PresbyterianSaintLuke’sMedical,Denver,CO(Dr JenniferClark);Roswell ParkCancer Institute, Buffalo,NY(Dr
Martin Brecher); Saint Barnabas Medical Center (Newark Beth Israel Medical Center), Livingston, NJ (Dr Stacey Rifkin-Zenenberg);
SaintChristopher’sHospital forChildren,Philadelphia, PA(DrGregoryHalligan); Saint JohnHospital andMedicalCenter,GrossPointe
Woods,MI (DrHadi Sawaf); Saint JosephChildren’sHospital ofTampa,Tampa, FL (DrHardeoPanchoosingh); Saint Joseph’sRegional
MedicalCenter, Peterson,NJ (DrMaryBonilla); Saint JudeChildren’sResearchHospital,Memphis, TN(DrWayneFurman); Saint Jude
Bielack et al
© 2015 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
144.82.107.89
Information downloaded from jco.ascopubs.org and provided by at UCL Library Services on June 19, 2015 from
Copyright © 2015 American Society of Clinical Oncology. All rights reserved.
Midwest Affiliate, Peoria, IL (Dr PedroDeAlarcon); Saint Luke’sMountain States Tumor Institute, Boise, ID (Dr Eugenia Chang); Saint
Mary’s Hospital, West Palm Beach, FL (Dr Narayana Gowda); Saint Peter’s University Hospital, New Brunswick, NJ (Dr Stanley
Calderwood); Saint Vincent Hospital, Green Bay, WI (Dr John Hill); Saint Vincent Hospital and Health Services, Indianapolis, IN (Dr
BassemRazzouk); San Jorge Children’s Hospital, Santurce, PR (Dr Luis Clavell); SanfordMedical Center-Fargo, Fargo, ND (DrNathan
Kobrinsky); Sanford USD Medical Center - Sioux Falls, Sioux Falls, ND (Dr Kayelyn Wagner); Santa Barbara Cottage Hospital, Santa
Barbara, CA (Dr Daniel Greenfield); Scott and White Memorial Hospital, Temple, TX (Dr Guy Grayson); Seattle Children’s Hospital,
Seattle, WA (Dr Douglas Hawkins); Sinai Hospital of Baltimore, Baltimore, MD (Dr Joseph Wiley); Southern California Permanente
Medical Group, Los Angeles, CA (Dr Robert Cooper); Southern Illinois University School of Medicine, Springfield, IL (Dr Gregory
Brandt); StateUniversityofNewYorkUpstateMedicalUniversity, Syracuse,NY(DrKarolKerr); StonyBrookUniversityMedicalCenter,
Stony Brook, NY (Dr Robert Parker); T C Thompson Children’s Hospital, Chattanooga, TN (Dr Manoo Bhakta); Tampa General
Hospital, Tampa, FL (Dr Cameron Tebbi); Texas Tech University Health Science Center-Amarillo (Children’ Hospital of San Antonio,
San Antonio, TX (Dr Osvaldo Regueira); The Children’s Medical Center of Dayton (Dayton Children’s Hospital), Dayton, OH (Dr
Emmett Broxson); The Steven and Alexandra Cohen Children’sMedical Center of New York, NewHyde Park, NY (Dr Arlene Redner);
TheToledoHospital/ToledoChildren’sHospital, Toledo,OH (DrDagmar Stein); TheUniversity of ArizonaMedical Center-University
Campus, Tuscon, AZ (Dr BrendaWittman); Tripler ArmyMedical Center, Fort SamHouston, TX (DrDellaHowell); UMDNJ - Robert
Wood JohnsonUniversityHospital (RutgersCancer Institute ofNew Jersey),NewBrunswick,NJ (DrRichardDrachtman);University of
Arkansas forMedical Sciences (ArkansasChildren’sHospital), Little Rock, AK (DrDavidBecton);University ofCaliforniaDavis-Cancer
Center, Sacramento, CA (Dr JayMichael Balagtas); University of California San FranciscoMedical Center-Parnassus, San Francisco, CA
(Dr Robert Goldsby); University of Chicago, Chicago, IL (Dr Susan Cohn); University of Florida, Gainesville, FL (DrWilliam Slayton);
University of Hawaii, Honolulu, HI (Dr Robert Wilkinson); University of Illinois, Chicago, IL (Dr Mary Schmidt); University of Iowa
Hospitals andClinics, IowaCity, IA (DrAymanEl-Sheikh); University of Kentucky, Lexington, KY (DrMarthaGreenwood); University
ofMarylandGreenebaumCancerCenter, Baltimore,ND (DrTeresa York);University ofMassachusettsMedical School,Worcester,MA
(Dr Christopher Keuker); University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, FL (Dr Julio Barredo);
University of Minnesota Medical Center-Fairview, Minneapolis, MN (Dr Joseph Neglia); University of Mississippi Medical Center,
Jackson, MS (Dr Gail Megason); University of Missouri-Columbia (MUHC-Women and Children’s Hospital), Columbia, MO (Dr
ThomasLoew);UniversityofNebraskaMedicalCenter,Omaha,NE(DrPeterCoccia);UniversityofNewMexico,Albuquerque,NM(Dr
Koh Boayue); University of North Carolina at Chapel Hill, Chapel Hill, NC (Dr Stuart Gold); University of Oklahoma Health Sciences
Center,OklahomaCityOK(DrReneMcNall-Knapp);University ofRochester, Rochester,NY (Dr JeffreyAndolina);University of South
Alabama, Mobile, AL (Dr Felicia Wilson); University of Texas Health Science Center, San Antonio, TX (Dr Anne-Marie Langevin);
University of Texas Southwestern Medical Center, Dallas, TX (Dr Naomi Winick); University of Vermont, Burlington, VT (Dr Alan
Homans); University of Virginia, Charlottesville, VA (DrKimberlyDunsmore); University ofWisconsinHospital andClinics,Madison,
WI (Dr Kenneth De Santes); Vanderbilt University, Nashville, TN (Dr Haydar Frangoul); Wake Forest University Health Sciences,
Winston-Salem, NC (Dr Thomas McLean); Walter Reed National Military Medical Center, Fort SamHouston, TX (Dr Della Howell);
WashingtonUniversitySchoolofMedicine, StLouis,MO(DrRobertHayashi);WayneStateUniversity,Detroit,MI (DrZhihongWang);
Weill Medical College of Cornell University, New York, NY (Dr Alexander Aledo); William Beaumont Hospital (Beaumont Children’s
Hospital-Royal Oak), Royal Oak, MI (Dr Charles Main); Winthrop University Hospital, Mineola, NY (Dr Mark Weinblatt); Yale
University, NewHaven, CT (DrNina Kadan-Lottick); Covenant Children’s Hospital, Lubbock, TX (Dr Latha Prasannan); Dana-Farber
Cancer Institute, Boston,MA (Dr Carlos Rodriguez-Galindo); Dartmouth HitchcockMedical Center, Lebanon, NH (Dr Sara Chaffee);
DellChildren’sMedicalCenter ofCentralTexas,Austin,TX(DrSharonLockhart);DriscollChildren’sHospital,CorpusChristie, TX(Dr
M. Cris Johnson); Duke UniversityMedical Center, Durham, NC (Dr Susan Kreissman); East Carolina University, Greeneville, NC (Dr
Mauro Grossi); East Tennessee Childrens Hospital, Knoxville, TN (Dr Ray Pais); EasternMaineMedical Center, Brewer, ME (Dr Sarah
Fryberger);GeorgiaRegentsUniversity,Augusta,GA(DrColleenMcDonough);HackensackUniversityMedicalCenter,Hackensack,NJ
(DrBurtonAppel);HelenDeVosChildren’sHospital atSpectrumHealth,GrandRapids,MI(DrDavidDickens);HurleyMedicalCenter,
Flint,MI (DrSusumuInoue); InovaFairfaxHospital, FallsChurch,VA(DrMarshall Schorin); JohnsHopkinsUniversity,Baltimore,MD
(Dr Kenneth Cohen); Kaiser Permanente-Oakland, Oakland, CA (Dr Steven Bergstrom); Kosair Children’s Hospital, Louisville, KY (Dr
Salvatore Bertolone); Lehigh Valley Hospital - Muhlenberg, Bethlehem, PA (Dr Philip Monteleone); Loma Linda University Medical
Center, LomaLinda,CA (DrAntranikBedros); LoyolaUniversityMedical Center,Maywood, IL (DrRicarchitoManera); Lucile Packard
Children’sHospital StanfordUniversity,PaloAlto,CA(DrNeyssaMarina);MDAndersonCancerCenter,Houston,TX(DrNajatDaw);
Madigan ArmyMedical Center, Fort Sam Houston, TX (Dr Della Howell); Maine Children’s Cancer Program, Scarsborough, ME (Dr
Eric Larsen); Mark O Hatfield-Warren Grant Magnuson Clinical Center, Bethesda, MD (Dr Crystal Mackall); Marshfield Clinic,
Marshfield, WI (Dr Michael McManus); Mary Bridge Children’s Hospital and Health Center, Tacoma, WA (Dr Robert Irwin);
MassachusettsGeneralHospitalCancerCenter,Boston,MA(DrHowardWeinstein);MattelChildren’sHospitalUCLA,LosAngeles,CA
(Dr Pamela Kempert); Mayo Clinic, Rochester, MN (Dr Carola Arndt); Medical City Dallas Hospital, Dallas, TX (Dr Carl Lenarsky);
Medical University of South Carolina, Charleston, SC (Dr Jacqueline Kraveka);MedStar GeorgetownUniversity Hospital,Washington,
DC(DrAzizaShad);MemorialRegionalHospital/JoeDiMaggioChildren’sHospital,Hollywood,FL(Dr IftikharHanif);Memorial Sloan
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Kettering Cancer Center, New York, NY (Dr Peter Steinherz); Memorial University Medical Center, Savannah, GA (Dr J. Martin
Johnston); Mercy Children’s Hospital, Toledo, OH (Dr Rama Jasty); Mercy Hospital Saint Louis, St Louis, MO (Dr Robin Hanson);
Methodist Children’sHospital of South Texas, SanAntonio, TX (Dr Jaime Estrada);Miami Children’sHospital,Miami, FL (Dr Enrique
Escalon);Michigan StateUniversity Clinical Center, East Lansing,MI (DrRenukaGera); NewYorkUniversity LangoneMedical Center,
(Dr Elizabeth Raetz).
Canada. AlbertaChildren’sHospital, Calgary,AB (DrDouglas Strother);AllanBlairCancerCentre,Regina, SK (DrMansoorHaq);
British Columbia Children’s Hospital, Vancouver, BC (Dr Caron Strahlendorf); Cancer Centre of Southeastern Ontario at Kingston
General Hospital, Kingston, ON (DrMariana Silva); CancerCareManitoba,Winnipeg, MB (Dr Rochelle Yanofsky); Centre Hospitalier
Universitaire Sainte-Justine,Montreal,QC(DrYvanSamson);Children’sHospital, London,ON(DrAnneCairney);Children’sHospital
of Eastern Ontario, Ottawa, ON (Dr Jacqueline Halton); CHU de Quebec, Quebec, PQ (Dr BrunoMichon); Saskatoon Cancer Centre,
Saskatoon, SK (Dr ChristopherMpofu); TheMontreal Children’s Hospital of theMUHC,Montreal, QC (Dr Sharon Abish); University
ofAlbertaHospital, Edmonton,AB (Dr Sunil JayantilalDesai);Hospital for SickChildren, Toronto,ON(DrRonaldGrant); IWKHealth
Centre, Halifax, NS (Dr Margaret Yhap); Janeway Child Health Centre, St John’s, NF (Dr Lisa Anne Goodyear); McMaster Children’s
Hospital at Hamilton Health Sciences, Hamilton, ON (Dr Carol Portwine).
Australia. Monash Medical Center-Clayton Campus, Clayton, VIC (Dr Peter Downie); Princess Margaret Hospital for Children,
Perth, WA. (Dr Catherine Cole); Royal Children’s Hospital, Parkville, VIC (Dr Francoise Mechinaud); Royal Childrens Hospital-
Brisbane, Brisbane, QLD (DrHelen Irving); Sydney Children’s Hospital, Randwick, NSW (DrDraga Barbaric); The Children’s Hospital
at Westmead, Westmead, NSW (Dr Geoffrey McCowage); Women’s and Children’s Hospital-Adelaide, North Adelaide, SA (DrMaria
Kirby).
Switzerland. Swiss Pediatric Oncology Group - Bern, Bern (Dr Roland Ammann); Swiss Pediatric Oncology Group - Geneva,
Geneva (DrMarc Ansari); Swiss Pediatric Oncology Group - Lausanne, Lausanne (DrMaja Beck Popovic).
New Zealand. Christchurch Hospital, Christchurch (DrMichael Sullivan); Starship Children’s Hospital, Auckland (Dr Teague).
Mexico. Hospital Infantil deMexico Federico Gomez, Mexico City (Dr AuroraMedina-Sanson).
COG Panel Representatives and Additional Contributors
NeyssaMarina, Chief Investigator; TMGMember: Chief Investigator; National Coordinator; Oncology Panel
Mark Bernstein, Chief Investigator; TMGChair; National Coordinator; Oncology Panel
CarolineWang, TMGMember: Research Coordinator
Justin Davis, TMGMember: Research Coordinator
Possidonia Gontijo, TMGMember: Research Coordinator
Mark Krailo, TMGMember: Statistician
Statistics Panel:
Allen Goorin, Oncology Panel
Paul Meyers, Oncology Panel
Lisa Teot,* Pathology Review Panel
Richard Gorlick,* Biological Studies Panel
Chand Khanna, Biological Studies Panel
Ching Lau, Biological Studies Panel
Doug Letson,* Surgical Panel
Mark Gebhardt, Surgical Panel
Lor Randall, Surgical Panel
JamesMeyer, Radiology Panel
Helen Nadel, Radiology Panel
Paula Schomberg, Radiotherapy Panel
Amy Barr, Pharmacy Panel
(*) Group representative
A2. Cooperative Osteosarkom Studiengruppe (COSS)
Austria. (Univers) Kinderklinik, Graz (Herrn Univ. Prof. Dr C. Urban); Univers. Kinderklinik, Innsbruck (Herrn Prof. Dr B.
Meister); LKA Salzburg, Salzburg (Herrn OADr N. Jones).
Czech Republic. Univ. ChildrensHosp. Brno, Brno (Herrn Prof. Dr P.Mudry); UniversityHospitalMOTOL, Prag (HerrnDrmed.
H.Mottl).
Germany. Universitätskinderklinik, Aachen (Herrn Prof. Dr R. Mertens); Krh. -Zweckverband Augsburg, Augsburg (Frau OA¨ Dr
A. K.Gnekow); Zentralklinikum,Augsburg (Herrn Prof. DrG. Schlimok);Helios KlinikenBad Saarow, Bad Saarow (Herrn PDDrmed.
Reichardt); Sozialstiftung Bamberg, Klinikum amBruderwald, Bamberg (Herrn Priv.-Doz. Drmed. Roland Repp); KlinikumBayreuth,
Bayreuth (Herrn Prof. Dr Th. Rupprecht); Charité Campus Virchow Klinikum Berlin, Berlin (Frau Prof. Dr med. A. Eggert); Ev.
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Waldkrankenhaus Spandau, Berlin (Herrn Dr Potenberg); Ev. Waldkrankenhaus Spandau, Berlin (Herrn Prof. Dr Noack); Helios
Klinikum Berlin - Buch, Berlin (Herrn PD Dr med. Reichardt); Helios Klinikum Berlin-Buch; Klinik für Kinder und Jugendmedizin,
Berlin (Herrn Prof. Dr L. Schweigerer); Charite, Berlin (Herrn Dr Jan Eucker); Charite - Campus VirchowKlinikum, Berlin (HerrnOA
Dr P. Thuss-Patience); Ev. Krankenhaus Bielefeld gGmbH, Bielefeld (Herrn OA Dr Jorch); Ev. Krankenhaus, Bielefeld (Herrn PD Dr
med. F. Weißinger); Univers. Kinderklinik, Bonn (Herrn Dr med. Stefan Schönberger); Städt. KlinikumHolwedestraße, Braunschweig
(Herrn OA Dr med. Eberl); Klinikum Bremen - Mitte gGmbh / Prof.-Hess-Kinderklinik, Bremen (Herrn Prof. Dr Pekrun); Klinikum
Bremen-Mitte, Bremen (Frau Dr med. Henrike Thomssen); Ev. Diakonie-Krankenhaus, Bremen (Herrn Prof. Dr Pflüger); Klinikum
Chemnitz, Chemnitz (Herrn OA Dr med. A. Hofmann); Klinikum Chemnitz gGmbH, Chemnitz (Herrn PD Dr med. M. Hänel);
Kliniken Dortmund, Dortmund (Frau Dr S. Bäumer); Städt. Kliniken, Dortmund (Herrn Prof. Dr med. Schneider); Univers. Kinderk-
linik,Dresden (HerrnProf.Drmed.M. Suttorp);Med.Universitätsklinik I,Dresden (HerrnPDDrG. Folprecht);Univers. Kinderklinik,
Düsseldorf (Herrn Prof. Dr Borkhardt); Med. Universitätsklinik & Poliklinik, Düsseldorf (Herrn Prof. Dr R. Haas); Helios Klinikum
Erfurt, Erfurt (Herrn CA PD Dr Sauerbrey); Universitätsklinikum Erlangen Kinder- und Jugendklinik, Erlangen (Herrn PD Dr med.
Markus Metzler); Universitätsklinikum Erlangen, Erlangen (Herrn PD Dr med. Spriewald); Waldkrankenhaus St. Marien, Erlangen
(HerrnPDDrmed.G.Preclik);Univers.Kinderklinik,Essen(Prof.DrBernhardKremens);Univers.Kinderklinik,Frankfurt (HerrnProf.
Dr Klingebiel); Universitätsklinik, Frankfurt (Herrn Prof. Dr Bergmann); Universitätsklinikum Freiburg Zentrum für Kinder- und
Jugendmedizin, Freiburg (Frau Prof. Dr med. Charlotte Niemeyer); Klinik Sanafontis, Freiburg (Herrn Dr med. J. Rentschler); Klinik
Sanafontis, Freiburg (Herrn PD Dr med. J. Drevs); Univers. Kinderklinik, Gießen (Herrn Prof. Dr Reiter); Univ. Klinikum Gießen,
Gießen (Herrn Prof. Drmed.M. Rummel); Universitätskinderklinik Göttingen, Göttingen (Herrn Prof. Drmed. Lakomek);Medizinis-
cheKlinik&Poliklinik, Göttingen (Herrn Prof. Dr L. Trümper); Univ. KlinikumGreifswald, Greifswald (Herrn Prof. Drmed.H. Lode);
UniversitätsmedizinGreifswald,Greifswald (HerrnDrChristian-Andreas Schmidt); Krankenhaus St. Elisabeth / St. Barbara,Halle (Frau
OA¨DrG. Günther);Med. Universitätsklinik / Innere IV, Halle (HerrnDrmed. H.-H.-Wolf); Universitätsklinik f. Kinder & Jugendme-
dizin, Halle / Saale (Herrn Prof. Dr Körholz); Univers. Kinderklinik, Hamburg (Herrn Dr med. Hassenpflug); Med. Hochschule
Hannover, Hannover (Herrn Prof. Dr A. Beilken);MHHZentrum InnereMedizin, Hannover (Herrn Prof. Drmed. ChristophReuter);
Klinikum Siloah, Hannover (Herrn PD Dr Kirchner); Univers. Klinik f. Kinder & Jugendmedizin, Heidelberg (Herrn OA Dr med.
WolfgangBehnisch);Med.Klinik&PoliklinikV,Heidelberg (FrauOA¨ Prof.Dr Egerer);Orthop.Universitätsklinik I,Heidelberg (Herrn
Prof. Dr Ewerbeck); SLKKlinikenHeilbronn,Heilbronn (FrauDrM. Streiter); GemeinschaftskrankenhausHerdecke,Herdecke (Herrn
Dr med. A. Längler); Univers. Kinderklinik, Homburg (Herrn Prof. Dr Graf); Med. Universitätsklinik I, Homburg (Herrn Prof. Dr
Pfreundschuh); Univers. Kinderklinik, Jena (Herrn OA. Dr med. Gruhn); Universitätsklinikum Jena, Jena (Herrn Dr med. Schmalen-
berg); Städt. Klinikum Karlsruhe, Karlsruhe (Herrn Dr med. A. Leipold); Klinikum Kassel, Kassel (Frau PD Dr med. Nathrath);
Universitätsklinikum Schleswig - Holstein, Kiel (Herrn Prof. Dr M. Schrappe); Universitätsklinikum Schleswig-Holstein, Kiel (Herrn
Prof. Dr Kneba); Gemeinschaftsklinikum Kemperhof Koblenz, Koblenz (Herrn OA Dr Ferrari); Uniklinik Köln, Köln (Herrn Prof. Dr
med. T. Simon); Med. Universitätsklinik I, Köln (Herrn Prof. J-M. Chemnitz); Helioskliniken Krefeld, Krefeld (Herrn Thomas Im-
schweiler);Univers.KinderklinikLeipzig, Leipzig (HerrnProf.Drmed.Christiansen);UniversitätsklinikumLeipzig, Leipzig (HerrnProf.
Drmed.Drh. c.Niederwieser); Landes- Frauen- undKinderklinik Linz, Linz (HerrnProf.DrK. Schmitt);Univers. Kinderklinik, Lübeck
(Herrn PDDrmed. M. Lauten); Klinikum Lüdenscheid, Lüdenscheid (Herrn Prof. Dr med. G. Heil); Klinikum d. Stadt Ludwigshafen,
Ludwigshafen (Herrn Prof. Dr Uppenkamp); St. Marien u. St. Annastiftskrankenhaus Ludwigshafen/Rh, Ludwigshafen (Abteilung
aufgelöst); UniversitätsklinikumMagdeburg A.ö.RUniversitätskinderklinik,Magdeburg (Herrn Prof. Drmed. Vorwerk);Med. Univer-
sitätsklinik III,Mainz (HerrnOADrH. J. Beck);Univers.KinderklinikMainz,Mainz (HerrnPDDr JörgFaber);Universitätskinderklinik
Mannheim, Mannheim (Herrn PD Dr Dürken); Univers. Kinderklinik, Marburg (Frau Dr med. Barbara Schütz); Johannes Wesling
KlinikumMinden,Minden (Herrn PDDr Erdlenbruch); Kinderklinik & Poliklinik d. TUMünchen,München (Frau PDDrmed. Irene
Teichert von Lüttichau); III. Medizinische Klinik & Poliklinik re. d. Isar, München (Herrn PDDr I. Ringshausen); Dr vonHaunersches
Kinderspital,München (FrauOA¨ PDDrmed. I. Schmid); KlinikumGroßhadern,München (Herrn PDDr Lars Lindner);Medizinische
Klinik & Poliklinik, Münster (Herrn Prof. Dr Berdel); Universitätsklinikum Münster, Münster (Herrn Prof. Dr Jürgens); Cnopf´sche
Kinderklinik, Nürnberg (Herrn Prof Dr Scheurlen); Med. Universitätsklinik V, Nürnberg (Herrn Prof. DrM.Wilhelm); Pius-Hospital,
Oldenburg (Herrn Prof. Dr F. Griesinger); Klinikum Oldenburg gGmbH, Oldenburg (Herr Prof. Dr Müller); Brüderkrankenhaus St.
Josef Paderborn, Paderborn (Herrn CADrmed. T. Gaska); Klinikum Passau, Passau (Herrn CA PDDr T. Südhoff); Krhs. Barmherzige
Brüder, Regensburg (HerrnProf.Drmed. JanBraess);Med.Universitätsklinik, Regensburg (FrauDrmed.Ch.Hart);Univ.Kinderklinik
Regensburg, Regensburg (Herrn Prof.Drmed.Corbacioglu);UniversitätsklinikumRostock, Rostock (Herrn PDDrmed.C. F. Classen);
Diakoniekrankenhaus Rotenburg, Rotenburg (HerrnDrmed. F.Heits); KlinikumSaarbrücken, Saarbrücken (HerrnDr JoachimWeis);
Diakonie - Klinikum, Schwäbisch Hall (Herrn Dr Thomas Geer); Helios Kliniken Schwerin, Schwerin (Herrn OA Dr med. Kasbohm);
Heliosklinikum Schwerin, Schwerin (Herrn Dr D. Hähling); Asklepios Klinik St. Augustin, St. Augustin (Herrn Dr med. Harald
Reinhard); Klinikum Stuttgart; Zentrum für Kinder- und Jugendmedizin - Olgahospital, Stuttgart (Herrn Prof. Dr Bielack); Diakonie-
Klinikum-Stuttgart, Stuttgart (Frau Prof. Dr Heidemann); Marienhospital, Stuttgart (Herrn Prof. Dr med. Denzlinger); Klinikum
Stuttgart/Krh. Bad Cannstatt, Stuttgart (Herrn Prof. Dr med. Andus); Univers. Kinderklinik, Tübingen (Herrn Prof. Dr med. Rupert
Handgretinger); Univers. Kinderklinik & Poliklinik, Ulm (Herrn Prof. Dr Debatin).
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